Please use this identifier to cite or link to this item:
http://hdl.handle.net/123456789/26342
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sahoo, Alaka | - |
dc.contributor.author | Fuloria, Shivkanya | - |
dc.contributor.author | Swain, Shasank Sekhar | - |
dc.contributor.author | Panda, Sujogya Kumar | - |
dc.contributor.author | Sekar, Mahendran | - |
dc.contributor.author | Subramaniyan, Vetriselvan | - |
dc.contributor.author | Panda, Maitreyee | - |
dc.contributor.author | Jena, Ajaya K. | - |
dc.contributor.author | Sathasivam, Kathiresan V | - |
dc.contributor.author | Fuloria, Neeraj Kumar | - |
dc.contributor.author | (UniKL RCMP) | - |
dc.date.accessioned | 2022-11-25T03:36:49Z | - |
dc.date.available | 2022-11-25T03:36:49Z | - |
dc.date.issued | 2021-11 | - |
dc.identifier.citation | Sahoo, A., Fuloria, S., Swain, S. S., Panda, S. K., Sekar, M., Subramaniyan, V., Panda, M., Jena, A. K., Sathasivam, K. V., & Fuloria, N. K. (2021). Potential of Marine Terpenoids against SARS-CoV-2: An In Silico Drug Development Approach. Biomedicines, 9(11), 1505. https://doi.org/10.3390/biomedicines9111505 | en_US |
dc.identifier.issn | 22279059 | - |
dc.identifier.uri | https://www.mdpi.com/journal/biomedicines | - |
dc.identifier.uri | http://hdl.handle.net/123456789/26342 | - |
dc.description.abstract | In an emergency, drug repurposing is the best alternative option against newly emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. However, several bioactive natural products have shown potential against SARS-CoV-2 in recent studies. The present study selected sixty-eight broad-spectrum antiviral marine terpenoids and performed molecular docking against two novel SARS-CoV-2 enzymes (main protease or Mpro or 3CLpro) and RNA-dependent RNA polymerase (RdRp). In addition, the present study analysed the physiochemical-toxicitypharmacokinetic profile, structural activity relationship, and phylogenetic tree with various computational tools to select the ‘lead’ candidate. The genomic diversity study with multiple sequence analyses and phylogenetic tree confirmed that the newly emerged SARS-CoV-2 strain was up to 96% structurally similar to existing CoV-strains. Furthermore, the anti-SARS-CoV-2 potency based on a protein-ligand docking score (kcal/mol) exposed that the marine terpenoid brevione F (-8.4) and stachyflin (-8.4) exhibited similar activity with the reference antiviral drugs lopinavir (-8.4) and darunavir (-7.5) against the target SARS-CoV-Mpro. Similarly, marine terpenoids such as xiamycin (-9.3), thyrsiferol (-9.2), liouvilloside B (-8.9), liouvilloside A (-8.8), and stachyflin (-8.7) exhibited comparatively higher docking scores than the referral drug remdesivir (-7.4), and favipiravir (-5.7) against the target SARS-CoV-2-RdRp. The above in silico investigations concluded that stachyflin is the most ‘lead’ candidate with the most potential against SARS-CoV-2. Previously, stachyflin also exhibited potential activity against HSV-1 and CoV-A59 within IC50, 0.16–0.82 uM. Therefore, some additional pharmacological studies are needed to develop ‘stachyflin’ as a drug against SARS-CoV-2. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MDPI | en_US |
dc.subject | Marine terpenoids | en_US |
dc.subject | Molecular docking | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Toxicity and drug-likeness profiles | en_US |
dc.title | Potential of marine terpenoids against sars-cov-2: An in silico drug development approach | en_US |
dc.type | Article | en_US |
Appears in Collections: | Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Potential of Marine Terpenoids.pdf | 4.56 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.